Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

La ecocardiografía con seguimiento de manchas como herramienta para el diagnóstico precoz de la alteración del crecimiento fetal en los embarazos gemelares (HEART)

16 de septiembre de 2026 actualizado por: University Hospital, Ghent

Ecocardiografía Speckle Tracking como herramienta para el diagnóstico precoz de la alteración del crecimiento fetal en embarazos gemelares

In this project there are 2 time points during the pregnancy included, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 21 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.

Descripción general del estudio

Descripción detallada

Fetal growth restriction (FGR) is diagnosed in 5-10% of the pregnancies. After preterm birth, it is the second leading cause of perinatal morbidity and mortality. Twin pregnancies have a higher occurrence of FGR than singletons, in monochorionic (MC) twin pregnancies it's diagnosed in 19.7% of the cases and in dichorionic (DC) twin pregnancies in 10.5% of the cases. Fetuses with FGR are at greater risk of perinatal morbidity and mortality and even long-term health defects. From a public health perspective, it's important to correctly diagnose FGR to adjust the antenatal and postnatal care and to have more insight into the factors influencing early onset cardiovascular disease. STE has a strong predictive value for cardiovascular function, therefore it would be a promising tool to add in the routine pregnancy clinical care. Speckle tracking echocardiography (STE) is a relative new technique especially in the pregnancy follow up, which permits offline calculation of myocardial velocities and deformation parameters. These parameters, including strain and strain rate, provide information about the fetal myocardial function. Apart from investigating if STE can be used for the prediction of FGR, we will also investigate the association between fetal exposure to air pollution and in utero cardiac remodeling. Indeed, it is known that inhalation of particulate matter (e.g. black carbon) during the pregnancy can reach the placenta and lead to alterations in the placenta's function including increases in oxidative stress markers. Early life exposure to black carbon has been associated with adverse cardiovascular health outcomes and reduction of fetal growth, especially in multiple gestation pregnancies.

In this project we will include 2 time points during the pregnancy, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 20 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.

Tipo de estudio

De observación

Inscripción (Estimado)

360

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Ghent, Bélgica, 9000
        • Reclutamiento
        • Ghent University Hospital
        • Contacto:
          • Kristien Roelens, prof. dr.
      • Leuven, Bélgica, 3000
        • Aún no reclutando
        • Universitair ziekenhuis Leuven
        • Contacto:
          • Liebeth Lewie, prof. dr.
      • Eindhoven, Países Bajos, 5631
        • Aún no reclutando
        • Maxima medical center
        • Contacto:
          • Judith van Laar, dr.

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 45 años (Adulto)

Acepta Voluntarios Saludables

N/A

Géneros elegibles para el estudio

Femenino

Método de muestreo

Muestra de probabilidad

Población de estudio

The number of subjects that will be included in this study is: 600 neonates (200 twin pairs and 200 singletons) and 400 pregnant mothers.

The fetuses are divided into following sub-groups:

  • Appropriately grown
  • Fetal growth restricted
  • Selective fetal growth restricted (specific for twins)

Descripción

Inclusion Criteria:

  • Singleton or dichorionic twin pregnancy
  • Pregnant women 21 weeks ( ± 2 weeks) of gestation at the first visit
  • Women ≥ 18 years

Exclusion Criteria:

  • Women pregnant of multiples of higher order (≥3 siblings) Monochorionic twin pregnancy
  • Fetal arrhythmia
  • Known fetal congenital or genetic abnormalities
  • Any suspicion of congenital fetal anomalies that might influence fetal cardiac function
  • Pre-existing maternal hypertensive disease
  • Autoimmune disease including systemic lupus erythematosus
  • History of stillbirth
  • Diabetes mellitus (mother)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: CASE_CONTROL
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Fetal growth restricted

Observation of cardiac remodeling perinatal and postnatal

blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth

Appropriately grown

Observation of cardiac remodeling perinatal and postnatal

blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To assess the change in strain measured by speckle tracking echocardiography as a tool for early diagnosis of impaired fetal growth in multiple gestations
Periodo de tiempo: Prenatal to 1-3 days after birth

to determine the change in fetal strain and strain rate in twin pregnancies in comparison with fetal growth

Prenatal to 1-3 days after birth
To determine the intra-pair differences in fetal growth and strain (cardiac remodeling) in multiple gestations.
Periodo de tiempo: Prenatal to 1-3 days after birth

to compare changes in strain and strain rate with fetal growth within 1 twin pair

Prenatal to 1-3 days after birth
To compare the strain values (cardiac remodeling) between singletons and twin pregnancies
Periodo de tiempo: Prenatal to 1-3 days after birth

to compare the changes in strain and strain rate between singletons and twin pregnancies

Prenatal to 1-3 days after birth

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To investigate the association between placenta functioning and in utero cardiac remodeling
Periodo de tiempo: Prenatal to 1-3 days after birth

to evaluate placenta insufficiency (Doppler ultrasound, biochemical marker) with strain and strain rate

Prenatal to 1-3 days after birth
To explore in utero cardiac remodeling in association with neonatal cardiovascular health
Periodo de tiempo: Prenatal to 1-3 days after birth

to evaluate strain and strain rate with the neonatale blood pressure and heart rate

Prenatal to 1-3 days after birth
To study the association between prenatal air pollution exposure and in utero cardiac remodeling
Periodo de tiempo: Prenatal to 1-3 days after birth

to evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with strain and strain rate

Prenatal to 1-3 days after birth
To investigate placenta functioning as a mediator between air pollution and cardiac remodeling
Periodo de tiempo: Prenatal to 1-3 days after birth

To evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with placenta insufficiency (biochemical marker, Doppler ultrasound)

Prenatal to 1-3 days after birth

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Kristien Roelens, University Hospital, Ghent

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de junio de 2023

Finalización primaria (Estimado)

1 de febrero de 2027

Finalización del estudio (Estimado)

1 de febrero de 2028

Fechas de registro del estudio

Enviado por primera vez

31 de mayo de 2022

Primero enviado que cumplió con los criterios de control de calidad

14 de junio de 2022

Publicado por primera vez (Actual)

21 de junio de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

21 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir